[{"id":"29484e1c-4971-4849-b48d-3a23a5771f8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03038230","created_at":"2023-05-31T18:05:43.433Z","updated_at":"2024-07-02T16:36:30.565Z","phase":"Phase 1","brief_title":"MCLA-117 in Acute Myelogenous Leukemia","source_id_and_acronym":"NCT03038230","lead_sponsor":"Merus N.V.","biomarkers":" CLEC12A","pipe":"","alterations":" ","tags":["CLEC12A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tepoditamab (MCLA-117)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 07/01/2021","study_completion_date":" 07/01/2021","last_update_posted":"2021-05-10"}]